Semaglutide Produces Similar Weight Loss Regardless of Diabetes or Heart Disease Status
Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or cardiovascular disease, supporting its universal applicability for obesity.
Quick Facts
What This Study Found
Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or cardiovascular disease, supporting its universal applicability for obesity.
Key Numbers
Three randomized trials, 48-72 weeks duration. Weight changes compared between MASLD/MASH patients with and without type 2 diabetes.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or car
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
- Published In:
- Diabetes, obesity & metabolism, 27(2), 710-718 (2025)
- Authors:
- Armstrong, Matthew J, Okanoue, Takeshi(2), Sundby Palle, Mads, Sejling, Anne-Sophie, Tawfik, Mohamed, Roden, Michael
- Database ID:
- RPEP-09980
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Analysis shows semaglutide achieves similar weight loss whether or not patients have diabetes or cardiovascular disease, supporting its universal applicability for obesity.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09980APA
Armstrong, Matthew J; Okanoue, Takeshi; Sundby Palle, Mads; Sejling, Anne-Sophie; Tawfik, Mohamed; Roden, Michael. (2025). Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.. Diabetes, obesity & metabolism, 27(2), 710-718. https://doi.org/10.1111/dom.16065
MLA
Armstrong, Matthew J, et al. "Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.." Diabetes, 2025. https://doi.org/10.1111/dom.16065
RethinkPeptides
RethinkPeptides Research Database. "Similar weight loss with semaglutide regardless of diabetes ..." RPEP-09980. Retrieved from https://rethinkpeptides.com/research/armstrong-2025-similar-weight-loss-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.